TY - JOUR T1 - Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for <em>KRAS</em> Wild-type Metastatic Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 3531 LP - 3536 VL - 36 IS - 7 AU - TOSHIFUMI YAMAGUCHI AU - SATORU IWASA AU - KENGO NAGASHIMA AU - NOBUAKI IKEZAWA AU - TETSUYA HAMAGUCHI AU - HIROKAZU SHOJI AU - YOSHITAKA HONMA AU - ATSUO TAKASHIMA AU - NATSUKO OKITA AU - KEN KATO AU - YASUHIDE YAMADA AU - YASUHIRO SHIMADA Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3531.abstract N2 - Background/Aim: Panitumumab and cetuximab are known to be effective treatments for KRAS wild-type metastatic colorectal cancer (mCRC). However, it remains unclear which of these two biologic agents confers the greatest benefit when combined with irinotecan in patients with KRAS wild-type mCRC previously treated with fluoropyrimidine, oxaliplatin and irinotecan. Patients and Methods: Data, from 139 patients who received panitumumab or cetuximab, in combination with irinotecan, for KRAS wild-type mCRC previously treated with fluoropyrimidine, oxaliplatin and irinotecan were analyzed. The efficacy and safety of panitumumab plus irinotecan was compared to that of cetuximab plus irinotecan. Results: Baseline characteristics of the panitumumab plus irinotecan (n=42) and cetuximab plus irinotecan (n=97) groups were similar. Among patients with measurable lesions, the response rate was 34% in the panitumumab plus irinotecan group and 20% in the cetuximab plus irinotecan group. Median progression-free survival (PFS) was 4.3 and 5.7 months in the panitumumab and cetuximab groups, respectively. Median overall survival was 13.6 months with panitumumab and 11.2 months with cetuximab. Conclusion: Panitumumab plus irinotecan was well-tolerated and displayed a similar level of efficacy to that of cetuximab plus irinotecan. ER -